Vasopressin Production Cost Reports

The report provides a detailed analysis essential for establishing a Vasopressin production plant. It encompasses all critical aspects necessary for Vasopressin production, including the cost of Vasopressin production, Vasopressin plant cost, Vasopressin production costs, and the overall Vasopressin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Vasopressin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Vasopressin is a peptide hormone that regulates water balance by promoting kidney reabsorption of water and also causes vasoconstriction to maintain blood pressure. It includes treating central diabetes insipidus to control excessive urination and thirst from ADH deficiency. It is utilised as a second-line vasopressor in vasodilatory shock, like septic shock, to raise blood pressure via receptor activation on vascular smooth muscle.

It is also utilised to manage acute variceal or gastrointestinal bleeding through splanchnic vasoconstriction, pulmonary embolism to improve right ventricular function and reduce blood volume, and haemorrhagic shock to support vascular tone and platelet aggregation. Its common side effects include abdominal cramps, nausea, vomiting, diarrhoea, headache, dizziness, pale skin, sweating, tremor, etc.

The market for Vasopressin is influenced by the rising prevalence of conditions like diabetes insipidus, septic shock, and vasoplegic shock. The rise in ageing populations, along with expanded healthcare infrastructure and greater clinician awareness, boosts its market as a vasopressor and antidiuretic.

The growth in critical care for shock management, organ donor support, and analogues like desmopressin for haemophilia or enuresis, fuelled by sepsis incidence and innovations in delivery systems, supports its market. The industrial Vasopressin procurement is affected by government reference pricing, squeezing margins, high costs under unapproved drugs initiatives, reducing competition, and reliance on key API suppliers. Other factors include regulatory approvals, reimbursement dynamics, along biosimilars and generics affect its sourcing strategies.

Raw Material for Vasopressin Production

According to the Vasopressin production plant project report, the key raw materials used in the production of Vasopressin include Protected Amino Acids, -Resin, -Trifluoroacetic Acid (TFA), -Coupling Agents (DIC/HOBt), and -Oxidants.

Production Process of Vasopressin

The extensive Vasopressin production cost report consists of the following major industrial production process:

1. By Solid-Phase peptide Synthesis: The production process of Vasopressin involves a solid-phase peptide synthesis. First, the last building block (glycine) is attached to the resin, then one protected amino acid is added at a time using simple chemicals to link them. The chain is cut free with acid (TFA), then uses mild bleach, like iodine or hydrogen peroxide, to link the two Cys ends with a disulfide bridge. The product is purified by chromatography and dried to get Vasopressin as the final product.

Vasopressin is a nonapeptide hormone with the molecular formula C46H65N15O12S2 and a molecular weight of around 1084.23 g/mol. It appears as a white lyophilised powder, is highly soluble in water (miscible), and slightly soluble in methanol. It has a pKa around 10.26, with good stability in aqueous solutions but degradation by intestinal peptidases, limiting oral bioavailability. It has a cyclic structure with a disulfide bridge between Cys1 and Cys6, an amidated C-terminus (Gly-NH2), and binds to V1 (Gq-coupled, vasoconstrictive via IP3/DAG and calcium release) and V2 (Gs-coupled, antidiuretic via aquaporin-2 insertion) receptors. It has low protein binding (~30%), a volume of distribution of 0.14–0.2 L/kg, and rapid clearance primarily by renal and hepatic peptidases.